Michael Seth Altman
CIK 1746738 · Chief Financial Officer · last filed 2026-07-22
Michael Seth Altman is a Chief Financial Officer who has filed 16 SEC Form 4 insider transactions across 8 companies since 2020. The most recent filing, for FRNM, was dated Jul 22, 2026. Current disclosed insider exposure totals $23.9M across reported positions. 2 SEC filings were submitted jointly with ARYA Sciences Holdings IV.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LYRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
51 ASTOR PLACE, 10TH FLOOR
NEW YORK, NY 10003
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FRNM | 2,352,500 | $10.18 | $23.95M | $0 | 1 | 2026-07-22 | |
| ARYA Sciences Acquisition Corp IV (ARYD) Delisted | Chief Financial Officer | 0 | $6.64 | $0 | $0 | 2 | 2024-07-31 |
| NAUT | Director | 0 | $2.23 | $0 | $0 | 4 | 2024-06-17 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | — | $0.70 | — | $0 | 5 | 2024-06-14 |
| Perceptive Capital Solutions Corp (PCSC) Delisted | Chief Business Officer | 286,250 | $11.95 | $3.42M | $0 | 1 | 2024-06-13 |
| ARYA Sciences Acquisition Corp V (ARYE) Delisted | Chief Financial Officer | 499,000 | $10.36 | $5.17M | $0 | 1 | 2021-07-15 |
| Nautilus Biotechnology, Inc. (ARYA) Delisted | Chief Financial Officer | 499,000 | $11.16 | $5.57M | $0 | 1 | 2020-08-11 |
| Cerevel Therapeutics Holdings, Inc. (CATB) Delisted | Chief Financial Officer | 83,167 | $8.54 | $710.2K | $0 | 1 | 2020-06-09 |
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-22 | FRNM | Conv (C) | +2,066,250 | $0 | EDGAR |
| 2024-07-31 | ARYA Sciences Acquisition Corp IV (ARYD) Delisted | Disp (D) | −499,000 | $0 | EDGAR |
| 2024-06-17 | NAUT | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | Perceptive Capital Solutions Corp (PCSC) Delisted | Grant (A) | +286,250 | $2.86M | EDGAR |
| 2023-07-05 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | NAUT | Grant (A) | — | $0 | EDGAR |
| 2022-06-21 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-17 | NAUT | Grant (A) | — | $0 | EDGAR |
| 2021-07-15 | ARYA Sciences Acquisition Corp V (ARYE) Delisted | Grant (A) | +499,000 | $4.99M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.